Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004429 · ClinicalTrials.gov registry record · NA
Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis
A NA study, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00004429 is a NA study that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 25 participants.
The verdict
NCT00004429, a NA study, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Assess the clinical safety and long term effects of recombinant human growth hormone on a defined range of nutritional indices in malnourished chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Interventions
- DRUG growth hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1999-12 |
| Est. Completion | 2005-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004429
The ClinicalTrials.gov registry entry for NCT00004429 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FDA Office of Orphan Products Development, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which growth hormone is the first listed.
NCT00004429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004429 about?
NCT00004429 is a clinical study titled "Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis". OBJECTIVES: I. Assess the clinical safety and long term effects of recombinant human growth hormone on a defined range of nutritional indices in malnourished chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
What is the current status of trial NCT00004429?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 1999-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00004429?
The interventions under investigation include: growth hormone (DRUG).
Who is sponsoring clinical trial NCT00004429?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.